Correlation of Prostaglandin D2 with disease severity of adult asthma
DOI:
https://doi.org/10.32007/jfacmedbagdad.613,41676Keywords:
Asthma, PGD2, Eosinophil, Asthma biomarkers, Asthma Severity.Abstract
Background: Prostaglandin D2 (PGD2) is a lipid mediator appeared as a powerful activator that regulates the T-helper2 (TH2) and Type-2 innate lymphoid cells (ILC2), and functions as diagnostic marker and it has probable therapeutic targets for asthma.
Objectives: To define the role of Prostaglandin D2 biomarkers in disease severity, and to forecast disease risk and progression.
Patients and methods: A case control study was conducted on Forty four Iraqi asthmatic patients and 44 apparently healthy controls who were age and sex matched. Four ml of blood samples was taken from the study groups for the detection PGD2 using ELISA.
Results: The serum level of PGD2 was almost convergent between cases and control group (median= 36.5pg/ml and 35.1 pg/ml respectively). The high median serum concentration of PGD2 showed a strong statistically significant association with the severity of asthmatic patients (39.8 pg/ml) in severe cases compared to (30.84 pg/ml) in moderate cases (P value =0.005). The median concentration of serum PGD2 revealed a higher level in abnormal eosinophil, monocytes and total IgE (42 pg/ml), (48.9 pg/ml) and (38.5 pg/ml) respectively than the median concentration of normal counts.
Conclusions: Measuring serum PGD2 in asthmatics is crucial to predict disease susceptibility, severity and disease control.
Downloads
Downloads
Published
Issue
Section
License
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.